Nevertheless, down-regulation of IL-13Rα2 or targeting IL-13Rα2 by receptor targeted immunotherapeutic agents, such as IL-13-PE, IL-13Rα2 cancer vaccines or adoptive transfer of chimeric antigen receptor modified T cells targeting IL-13Rα2, may improve the prognosis of patients with PDAC. The gene discussed is IL13RA2; the disease is cancer.